Synlogic
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 6
- Market Cap
- $17.4M
- Website
- http://www.synlogictx.com
- Introduction
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
Clinical Trials
12
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
- Conditions
- Phenylketonuria
- Interventions
- Drug: SYNB1934v1Drug: Placebo
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 35
- Registration Number
- NCT05764239
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸Stanford University, Department of Pediatrics, Palo Alto, California, United States
Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 31
- Registration Number
- NCT05462132
- Locations
- 🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 11
- Registration Number
- NCT05377112
- Locations
- 🇺🇸
PPD, part of Thermo Fisher Scientific, Austin, Texas, United States
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 106
- Registration Number
- NCT04984525
- Locations
- 🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 77
- Registration Number
- NCT04629170
- Locations
- 🇺🇸
Urological Associates of Southern Arizona (open to remote participation), Tucson, Arizona, United States
🇺🇸Genesis Clinical Research, Tampa, Florida, United States
🇺🇸Knoxville Kidney Center, Knoxville, Tennessee, United States
- Prev
- 1
- 2
- Next
News
Synlogic's Novel Probiotic Therapy Shows Promise in Phase 2 PKU Trial, Advancing to Phase 3
Synlogic's engineered probiotic SYNB1934 demonstrated a significant 34% reduction in phenylalanine levels in phenylketonuria patients during Phase 2 trials, outperforming its predecessor SYNB1618.